China NT Pharma Group Company Limited (NT Pharma) announced the completion of its previously disclosed major transaction on 25 March 2026. The group has acquired 100% of the issued shares of three target companies and settled the consideration through the allotment of 274,751,679 new shares at an issue price of HK$0.45 per share. All conditions precedent in the Sale and Purchase Agreement and its supplemental agreement have been fulfilled, and the target companies are now indirect wholly owned subsidiaries of NT Pharma.

Following completion, NT Pharma indirectly holds 58.11% of Zhejiang Kangyuan Medical Equipment Co., Ltd., whose financial results will be consolidated into the group’s accounts.

The share issuance has expanded NT Pharma’s total outstanding shares by 40.74%, from 674.25 million to 948.99 million. Golden Base Investment Ltd. remains the largest shareholder but sees its stake diluted from 45.08% to 32.03%. Former sellers of the target companies collectively hold 274.75 million shares, representing 28.90% of the enlarged share capital, with the largest individual positions now belonging to: • Lou YongBin – 61.07 million shares (6.43%) • Lou YongJun – 47.33 million shares (4.99%) • Chen HongLi – 80.33 million shares (8.46%) • Zhang GenHuo – 79.40 million shares (8.37%)

Public shareholders other than the above parties now account for 17.76% of the issued shares, compared with 25.00% before the transaction.

The board composition remains unchanged, and the company states that all regulatory and listing requirements related to the issuance of consideration shares under the specific mandate have been satisfied.